Ulf Lindström
0000-0002-2250-9348
24 papers found
Refreshing results…
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
Comment on: Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: results from a national register-based cohort study. Reply
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice
Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study
Missing publications? Search for publications with a matching author name.